Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2018

Open Access 01-12-2018 | Research article

RHAMM induces progression of rheumatoid arthritis by enhancing the functions of fibroblast-like synoviocytes

Authors: Jing Wu, Yuan Qu, Yu-Ping Zhang, Jia-Xin Deng, Qing-Hong Yu

Published in: BMC Musculoskeletal Disorders | Issue 1/2018

Login to get access

Abstract

Background

Rheumatoid arthritis (RA) is a chronic and refractory autoimmune joint disease. Fibroblast-like synoviocytes (FLS) produce inflammatory cytokines and are involved in the migration and invasion of panuus tissue, which leads to the destruction of joints in RA. Receptor for hyaluronan mediated motility (RHAMM), is known to be one of the important receptors for hyaluronic acid. It has the ability to regulate migration of fibrocytes and infiltration of inflammatory cells. Here,we explored the mechanisms of RHAMM in RAFs.

Methods

Quantitative PCR and western blot were performed to test the expression of RHAMM in synoviocytes of RA patients and osteoarthritis (OA) controls. Collagen antibody-induced arthritis (CAIA) was used to investigate the RHAMM expression in mouse synovial issues. RHAMM siRNA was used to detect the function of RHAMM in FLS.

Results

RA-FLS has a significantly higher expression of RHAMM than OA-FLS. Expression of RHAMM in joint synovial tissue was markedly increased in the CAIA mice compared with the controls. RHAMM silencing using SiRNA was not only decreased the production of IL-6 and IL-8, but also inhibited the migration and invasion of RA-FLS.

Conclusions

RHAMM has an important role in the FLS induced modulation of inflammation and destruction of joints in RA.
Literature
1.
go back to reference Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.CrossRef Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.CrossRef
2.
go back to reference Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–108.CrossRef Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–108.CrossRef
3.
go back to reference Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33.CrossRef Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33.CrossRef
4.
go back to reference Filer A. The fibroblast as a therapeutic target in rheumatoid arthritis. Curr Opin Pharmacol. 2013;13:413–9.CrossRef Filer A. The fibroblast as a therapeutic target in rheumatoid arthritis. Curr Opin Pharmacol. 2013;13:413–9.CrossRef
5.
go back to reference McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19.CrossRef McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19.CrossRef
6.
go back to reference Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006;45:669–75.CrossRef Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006;45:669–75.CrossRef
7.
go back to reference Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223:252–70.CrossRef Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223:252–70.CrossRef
8.
go back to reference Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307–10.CrossRef Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307–10.CrossRef
9.
go back to reference Terenzi R, Romano E, Manetti M, Peruzzi F, Nacci F, Matucci-Cerinic M, et al. Neuropeptides activate TRPV1 in rheumatoid arthritis fibroblast-like synoviocytes and foster IL-6 and IL-8 production. Ann Rheum Dis. 2013;72:1107–9.CrossRef Terenzi R, Romano E, Manetti M, Peruzzi F, Nacci F, Matucci-Cerinic M, et al. Neuropeptides activate TRPV1 in rheumatoid arthritis fibroblast-like synoviocytes and foster IL-6 and IL-8 production. Ann Rheum Dis. 2013;72:1107–9.CrossRef
10.
go back to reference Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233–55.CrossRef Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233–55.CrossRef
11.
go back to reference Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009;15:1414–20.CrossRef Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009;15:1414–20.CrossRef
12.
go back to reference Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, et al. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia. 2009;11:956–63.CrossRef Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, et al. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia. 2009;11:956–63.CrossRef
13.
go back to reference Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, et al. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci. 2007;1110:233–47.CrossRef Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, et al. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci. 2007;1110:233–47.CrossRef
14.
go back to reference Garcia-Posadas L, Contreras-Ruiz L, Arranz-Valsero I, Lopez-Garcia A, Calonge M, Diebold Y. CD44 and RHAMM hyaluronan receptors in human ocular surface inflammation. Graefes Arch Clin Exp Ophthalmol. 2014;252:1289–95.CrossRef Garcia-Posadas L, Contreras-Ruiz L, Arranz-Valsero I, Lopez-Garcia A, Calonge M, Diebold Y. CD44 and RHAMM hyaluronan receptors in human ocular surface inflammation. Graefes Arch Clin Exp Ophthalmol. 2014;252:1289–95.CrossRef
15.
go back to reference Dunn S, Kolomytkin OV, Waddell DD, Marino AA. Hyaluronan-binding receptors: possible involvement in osteoarthritis. Mod Rheumatol. 2009;19:151–5.CrossRef Dunn S, Kolomytkin OV, Waddell DD, Marino AA. Hyaluronan-binding receptors: possible involvement in osteoarthritis. Mod Rheumatol. 2009;19:151–5.CrossRef
16.
go back to reference Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem. 2001;276:36770–8.CrossRef Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem. 2001;276:36770–8.CrossRef
17.
go back to reference Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A. 2004;101:18081–6.CrossRef Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A. 2004;101:18081–6.CrossRef
18.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–2581. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–2581.
19.
go back to reference Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Arthritis Rheum. 2000;43:1905–15. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Arthritis Rheum. 2000;43:1905–15.
20.
go back to reference Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of Laboratory Animals.: Guide for the care and use of laboratory animals. In: NIH publication. Bethesda, Md.: U.S. Dept. of Health and Human Services, Public Health Service: v. Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of Laboratory Animals.: Guide for the care and use of laboratory animals. In: NIH publication. Bethesda, Md.: U.S. Dept. of Health and Human Services, Public Health Service: v.
21.
go back to reference Ballard PL, Gonzales LW, Godinez RI, Godinez MH, Savani RC, McCurnin DC, et al. Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide. Pediatr Res. 2006;59:157–62.CrossRef Ballard PL, Gonzales LW, Godinez RI, Godinez MH, Savani RC, McCurnin DC, et al. Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide. Pediatr Res. 2006;59:157–62.CrossRef
22.
go back to reference Khan F, Ahmad SR. Polysaccharides and their derivatives for versatile tissue engineering application. Macromol Biosci. 2013;13:395–421.CrossRef Khan F, Ahmad SR. Polysaccharides and their derivatives for versatile tissue engineering application. Macromol Biosci. 2013;13:395–421.CrossRef
23.
go back to reference Breitkreutz D, Koxholt I, Thiemann K, Nischt R. Skin basement membrane: the foundation of epidermal integrity--BM functions and diverse roles of bridging molecules nidogen and perlecan. Biomed Res Int. 2013;2013:179784.CrossRef Breitkreutz D, Koxholt I, Thiemann K, Nischt R. Skin basement membrane: the foundation of epidermal integrity--BM functions and diverse roles of bridging molecules nidogen and perlecan. Biomed Res Int. 2013;2013:179784.CrossRef
24.
go back to reference Grisar J, Munk M, Steiner CW, Amoyo-Minar L, Tohidast-Akrad M, Zenz P, et al. Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30:64–72.PubMed Grisar J, Munk M, Steiner CW, Amoyo-Minar L, Tohidast-Akrad M, Zenz P, et al. Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30:64–72.PubMed
25.
go back to reference Turley EA, Naor D. RHAMM and CD44 peptides-analytic tools and potential drugs. Front Biosci (Landmark Ed). 2012;17:1775–94.CrossRef Turley EA, Naor D. RHAMM and CD44 peptides-analytic tools and potential drugs. Front Biosci (Landmark Ed). 2012;17:1775–94.CrossRef
26.
go back to reference Croxford AM, Whittingham S, McNaughton D, Nandakumar KS, Holmdahl R, Rowley MJ. Type II collagen-specific antibodies induce cartilage damage in mice independent of inflammation. Arthritis Rheum. 2013;65:650–9.CrossRef Croxford AM, Whittingham S, McNaughton D, Nandakumar KS, Holmdahl R, Rowley MJ. Type II collagen-specific antibodies induce cartilage damage in mice independent of inflammation. Arthritis Rheum. 2013;65:650–9.CrossRef
27.
go back to reference Nandakumar KS, Holmdahl R. Collagen antibody induced arthritis. Methods Mol Med. 2007;136:215–23.CrossRef Nandakumar KS, Holmdahl R. Collagen antibody induced arthritis. Methods Mol Med. 2007;136:215–23.CrossRef
28.
go back to reference Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. Am J Pathol. 1998;152:793–803.PubMedPubMedCentral Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. Am J Pathol. 1998;152:793–803.PubMedPubMedCentral
29.
go back to reference Tan PL, Farmiloe S, Yeoman S, Watson JD. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol. 1990;17:1608–12.PubMed Tan PL, Farmiloe S, Yeoman S, Watson JD. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol. 1990;17:1608–12.PubMed
30.
go back to reference Georganas C, Liu HT, Perlman H, Hoffmann A, Thimmapaya B, Pope RM. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol. 2000;165:7199–206.CrossRef Georganas C, Liu HT, Perlman H, Hoffmann A, Thimmapaya B, Pope RM. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol. 2000;165:7199–206.CrossRef
31.
go back to reference Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 2001a;167:5381–5.CrossRef Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 2001a;167:5381–5.CrossRef
32.
go back to reference Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 2001b;167:5381–5.CrossRef Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 2001b;167:5381–5.CrossRef
33.
go back to reference Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80.CrossRef Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80.CrossRef
34.
go back to reference Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–9.CrossRef Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–9.CrossRef
35.
go back to reference Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2006;33:463–71.PubMed Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2006;33:463–71.PubMed
36.
go back to reference Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK, Pope RM, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol. 1991;147:2187–95.PubMed Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK, Pope RM, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol. 1991;147:2187–95.PubMed
37.
go back to reference Kraan MC, Patel DD, Haringman JJ, Smith MD, Weedon H, Ahern MJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res. 2001;3:65–71.CrossRef Kraan MC, Patel DD, Haringman JJ, Smith MD, Weedon H, Ahern MJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res. 2001;3:65–71.CrossRef
Metadata
Title
RHAMM induces progression of rheumatoid arthritis by enhancing the functions of fibroblast-like synoviocytes
Authors
Jing Wu
Yuan Qu
Yu-Ping Zhang
Jia-Xin Deng
Qing-Hong Yu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2018
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-018-2370-6

Other articles of this Issue 1/2018

BMC Musculoskeletal Disorders 1/2018 Go to the issue